Predicting Visit Cost of Obstructive Sleep Apnea Using Electronic Healthcare Records With Transformer.

BACKGROUND: Obstructive sleep apnea (OSA) is growing increasingly prevalent in many countries as obesity rises. Sufficient, effective treatment of OSA entails high social and financial costs for healthcare. OBJECTIVE: For treatment purposes, predicting OSA patients' visit expenses for the coming year is crucial. Reliable estimates enable healthcare decision-makers to perform careful fiscal management and budget well for effective distribution of resources to hospitals. The challenges created by scarcity of high-quality patient data are exacerbated by the fact that just a third of those data from OSA patients can be used to train analytics models: only OSA patients with more than 365 days of follow-up are relevant for predicting a year's expenditures. METHODS AND PROCEDURES: The authors propose a translational engineering method applying two Transformer models, one for augmenting the input via data from shorter visit histories and the other predicting the costs by considering both the material thus enriched and cases with more than a year's follow-up. This method effectively adapts state-of-the-art Transformer models to create practical cost prediction solutions that can be implemented in OSA management, potentially enhancing patient care and resource allocation. RESULTS: The two-model solution permits putting the limited body of OSA patient data to productive use. Relative to a single-Transformer solution using only a third of the high-quality patient data, the solution with two models improved the prediction performance's [Formula: see text] from 88.8% to 97.5%. Even using baseline models with the model-augmented data improved the [Formula: see text] considerably, from 61.6% to 81.9%. CONCLUSION: The proposed method makes prediction with the most of the available high-quality data by carefully exploiting details, which are not directly relevant for answering the question of the next year's likely expenditure. Clinical and Translational Impact Statement: Public Health- Lack of high-quality source data hinders data-driven analytics-based research in healthcare. The paper presents a method that couples data augmentation and prediction in cases of scant healthcare data.

Value of genetic testing in the prevention of coronary heart disease events.

BACKGROUND: The health economic evidence about the value and optimal targeting of genetic testing in the prevention of coronary heart disease (CHD) events has remained limited and ambiguous. The objective of this study is to optimize the population-level use and targeting of genetic testing alongside traditional risk factors in the prevention of CHD events and, thereby, to assess the cost-benefit of genetic testing. METHODS AND FINDINGS: We compare several strategies for using traditional and genetic testing in the prevention of CHD through statin therapy. The targeting of tests to different patient segments within these strategies is optimized by using a decision-analytic model, in which a patient's estimated risk of CHD is updated based on test results using Bayesian methods. We adopt the perspective of healthcare sector. The data for the model is exceptionally wide and combined from national healthcare registers, the Finnish Institute for Molecular Medicine, and published literature. Our results suggest that targeting genetic testing in an optimal way to those patients about which traditional risk factors do not provide sufficiently accurate information results in the highest expected net benefit. In particular, compared to the use of traditional risk factors only, the optimal use of genetic testing would decrease the expected costs of an average patient aged 45 years or more by 2.54€ in a 10-year follow-up period while maintaining the level of the expected health outcome. Thus, genetic testing is found to be a part of a cost-beneficial testing strategy alongside traditional risk factors. This conclusion is robust to reasonable changes in model inputs. CONCLUSIONS: If targeted optimally, the use of genetic testing alongside traditional risk factors is cost-beneficial in the prevention of CHD.